The 2024–2025 flu vaccine is providing moderate protection, which is roughly in line with what’s typical for flu shots in most years. CDC interim estimates show the vaccine reduces outpatient flu illness by about 32% to 54% depending on age group and the tracking network, while protection against hospitalization ranges from 41% to 78%. Those numbers may sound modest, but they translate to a meaningful reduction in severe illness, especially for children and older adults.
How Effective the Vaccine Is This Season
Flu vaccine effectiveness varies by age, the strain making someone sick, and whether you’re measuring doctor visits or hospitalizations. For the 2024–2025 season, the CDC’s interim data from four surveillance networks paints the following picture.
For children and teens, protection against outpatient flu illness ranged from 32% to 60% across different tracking systems. Protection against hospitalization was stronger: 63% to 78%. That pattern holds most years. The vaccine may not always prevent infection, but it consistently reduces the chance of ending up in the hospital.
For adults, effectiveness against outpatient illness was 36% to 54%. Against hospitalization, it was 41% to 55%. Among adults 65 and older, vaccine effectiveness against hospitalization was 44%. That may seem low, but because vaccination rates are higher in this age group (about 63%), the CDC estimates that 81% of all flu deaths prevented by vaccination this season were in people 65 and older. Even moderate effectiveness at scale saves a significant number of lives.
The strongest hospitalization protection this season went to the youngest children: 61% effectiveness among kids aged 6 months to 4 years. The weakest was among adults 50 to 64, at 41%.
Performance Against Different Strains
Two influenza A strains have been circulating this season: H1N1 and H3N2. The vaccine’s performance differs depending on which one you’re exposed to.
Against H1N1, the vaccine performed reasonably well in children, with effectiveness of 53% to 72% in outpatient settings and 63% against hospitalization. In adults, it was less impressive: about 42% against outpatient illness, and the estimate against hospitalization (39%) was not statistically significant, meaning researchers couldn’t confirm it was different from zero with confidence.
Against H3N2, which is historically the harder strain to match, the numbers were mixed. In children, outpatient effectiveness was 42% and hospitalization protection was 55%. In adults, the vaccine showed 51% effectiveness against H3N2 hospitalization, but the outpatient estimate (25%) was not statistically significant. H3N2 strains mutate quickly, which often makes them the trickiest target for vaccine designers.
How Well the Vaccine Matched Circulating Viruses
Each year, the World Health Organization selects specific virus strains for inclusion in the vaccine months before flu season begins. For 2024–2025, the vaccine targeted an H1N1 strain, an H3N2 strain, and a B/Victoria influenza B strain. However, the viruses actually circulating this season have drifted genetically from the vaccine strains.
More than 80% of circulating H1N1 viruses belonged to a subclade called C.1.9, which carries a key mutation not present in the vaccine strain. Most circulating H3N2 viruses belonged to a different subclade (J.2) than the vaccine’s reference virus. Circulating influenza B viruses were a better match, aligning with the same broad clade as the vaccine component. This kind of partial mismatch is common and helps explain why effectiveness hovers in the moderate range rather than reaching the 70% or higher levels seen in well-matched years.
This Year’s Shift to Trivalent Vaccines
One notable change for 2024–2025: all U.S. flu vaccines switched from four components (quadrivalent) to three (trivalent). The dropped component targeted the B/Yamagata influenza lineage, which hasn’t been detected in global surveillance since March 2020. Because that lineage appears to no longer circulate, removing it from the vaccine doesn’t reduce protection. Quadrivalent vaccines were available in the U.S. from 2013–2014 through 2023–2024, but continuing to include a virus that’s effectively disappeared was no longer justified.
What the Southern Hemisphere Told Us
Countries in South America use a similar vaccine formula during their winter (March through July), providing an early preview of how the Northern Hemisphere season might go. Data from Argentina, Brazil, Chile, Paraguay, and Uruguay showed the 2024 Southern Hemisphere vaccine reduced flu-related hospitalizations by about 35% overall. Protection was strongest for people with chronic health conditions (59%) and young children (39%), and lowest for older adults (31%). Against the dominant H3N2 strain, effectiveness was 37%, and against H1N1 it was also 37%. These numbers foreshadowed the moderate performance now being confirmed in the U.S.
When Timing Affects Protection
Flu vaccine immunity doesn’t last indefinitely. Protection begins to wane over the course of the season, and this effect is most pronounced in older adults. This is why the CDC recommends getting vaccinated in September or October for most people, rather than July or August. Getting the shot too early risks having diminished protection by the time flu activity peaks, which often happens between December and February.
Children aged 6 months through 8 years who haven’t previously received at least two flu vaccine doses need two shots spaced at least four weeks apart. For these kids, starting earlier makes sense to ensure both doses are completed by late October. For everyone else, the September–October window balances building immunity in time for peak season against the risk of waning protection later in winter.
Putting Moderate Effectiveness in Context
A vaccine that’s 40% to 55% effective may not sound impressive compared to vaccines for measles or tetanus, but flu is a uniquely difficult target. The virus mutates constantly, and scientists must predict which strains will dominate months before the season starts. In that context, 40% to 55% is a normal, useful result.
Even at moderate effectiveness, the math works in your favor. A 50% reduction in your risk of hospitalization is substantial, particularly if you’re over 65, have a chronic condition, or are caring for young children. The vaccine also tends to reduce the severity and duration of illness even when it doesn’t prevent infection entirely, meaning vaccinated people who do get the flu are less likely to develop complications like pneumonia.